 | | Vol. 6.17 – 19 July, 2024 |
| |
|
|
| A newly discovered hsa-circ-0003764 was identified from the circbase database. QRT-PCR analysis was utilized to assess the expression levels of hsa-circ-0003764 in both HCC tissues and cells.
[Molecular Cancer] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors investigated the impact of high body weight and BMI on HCC survival using The Cancer Genome Atlas Liver Hepatocellular Carcinoma dataset.
[Human Genetics] |
|
|
|
| Scientists defined the proteomic and phosphoproteomic landscape of urinary small extracellular vesicles (sEVs) in patients with HCC. Mass spectrometry-based methods were used to detect the global proteome and phosphoproteome profiles of sEVs isolated by differential ultracentrifugation.
[Analyst] |
|
|
|
| Hydrodynamics-based transfection, employing the sleeping beauty transposase system, delivered surrogate tumor antigens, NRAS, ShP53, and SB100 to C57BL/6 mice.
[Journal of Gastroenterology and Hepatology] |
|
|
|
| Researchers investigated the cellular characteristics of circulating tumor cells focusing on monitoring during atezolizumab and bevacizumab therapy in patients with HCC. Peripheral blood samples were collected from 10 healthy controls and 40 patients with HCC.
[Heliyon] |
|
|
|
| Gene expression analysis on TIMER 2.0, UALCAN, and GEPIA databases was performed to measure the expression of MTIF2 in HCC tissues.
[Heliyon] |
|
|
|
|
|
| Investigators summarize the role of HNF4α in liver cancer pathogenesis and highlights its potential as a potential therapeutic target for HCC.
[Seminars in Liver Disease] |
|
|
|
| While there has been great progress in drug development and clinical trials for MASLD/MASH, the complexity of these pathways highlights the need to improve diagnosis/early detection and develop more successful antifibrotic therapies that not only prevent but reverse fibrosis.
[Annals of The New York Academy of Sciences] |
|
|
|
|
| UNSW Sydney will form part of a new network established by the NSW government to help reduce and replace animals in medical research.
[UNSW Sydney] |
|
|
|
| HepaRegeniX GmbH announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund, and High-Tech Gründerfonds.
[HepaRegeniX] |
|
|
|
|
| September 6-9, 2024
Breckenridge, Colorado, United States |
|
|
|
|
|
| | University of Hong Kong – Hong Kong, Hong Kong |
|
|
|
| | University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
| | National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | Goethe University Frankfurt am Main – Frankfurt, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
